Rep. Emily Randall Sells Abbott Laboratories (NYSE:ABT) Stock

Representative Emily Randall (D-Washington) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on February 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on January 6th. The trade occurred in the Representative’s “GARRET D. LEAHEY 2019 IRREVOCABLE F/B/O ALISON LEAHEY” account.

Representative Emily Randall also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 1/7/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Fortive (NYSE:FTV) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 1/6/2025.

Abbott Laboratories Trading Down 0.7 %

Shares of Abbott Laboratories stock opened at $130.48 on Thursday. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $132.50. The company’s fifty day simple moving average is $118.05 and its 200-day simple moving average is $115.60. The company has a market cap of $226.31 billion, a price-to-earnings ratio of 17.06, a PEG ratio of 2.39 and a beta of 0.75. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. During the same quarter in the previous year, the firm posted $1.19 EPS. The business’s revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Wednesday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.81%. Abbott Laboratories’s payout ratio is 30.85%.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at $16,152,064.50. This trade represents a 15.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.10% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently modified their holdings of ABT. Groupama Asset Managment raised its position in Abbott Laboratories by 22.2% in the 3rd quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 41,557 shares during the last quarter. Noble Wealth Management PBC acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at $26,000. NewSquare Capital LLC boosted its holdings in Abbott Laboratories by 78.4% in the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after acquiring an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in Abbott Laboratories in the fourth quarter worth about $28,000. Finally, Rialto Wealth Management LLC bought a new stake in Abbott Laboratories during the 4th quarter worth about $29,000. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the company. Mizuho raised their price objective on Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a research report on Thursday, October 17th. Jefferies Financial Group lifted their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research note on Thursday, October 17th. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 23rd. Morgan Stanley lifted their target price on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 17th. Finally, Piper Sandler raised their price target on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $133.06.

About Representative Randall

Emily Randall (Democratic Party) is a member of the U.S. House, representing Washington’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Randall (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 6th Congressional District. She declared candidacy for the 2026 election.

Emily Randall was born in Port Orchard, Washington, and lives in Bremerton, Washington. Randall earned bachelor’s degrees in Spanish and women’s studies from Wellesley College in 2008. Her career experience includes working as a development professional with Wellesley College, the San Francisco AIDS Foundation, Planned Parenthood Federation of America, and Legal Voice.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.